With a market cap of $35.2 billion, Agilent Technologies, Inc. (A) is a leading global provider of application-focused solutions for the life sciences, diagnostics, and applied chemical markets. The company operates through three core segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab, offering a diverse portfolio of instruments, consumables, software, and services.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Agilent Technologies fits this criterion perfectly. Agilent distributes its products primarily through a direct sales model, complemented by distributors, resellers, representatives, and e-commerce channels.
However, shares of the Santa Clara, California-based company have fallen over 18% from its 52-week high of $153.84. Shares of Agilent Technologies have risen 5.3% over the past three months, underperforming The Health Care Select Sector SPDR Fund’s (XLV) 2.8% gain over the same time frame.
www.barchart.com
Longer term, Agilent stock is down 6.1% on a YTD basis, lagging behind XLV’s 1.4% return. Moreover, shares of the scientific instrument maker have declined 9.1% over the past 52 weeks, compared to XLV’s 10.1% decrease over the same time frame.
Despite a few fluctuations, the stock has moved above its 50-day moving average since late May.
www.barchart.com
Shares of Agilent Technologies climbed 5.3% following its Q3 2025 results on Aug. 27, with adjusted EPS of $1.37 and revenue of $1.74 billion, exceeding estimates. Strength was driven by outperformance in its Life Sciences and Diagnostics segment, which posted $670 million in sales, and its CrossLab unit, which delivered $744 million. Boosting sentiment further, Agilent raised its full-year revenue guidance to $6.91 billion – $6.93 billion and tightened its EPS outlook to $5.56 – $5.59, signaling confidence in improving demand for its lab research and drug development tools.
In contrast, rival Eli Lilly and Company (LLY) has outpaced Agilent stock on a YTD basis, declining 1.8%. LLY stock has decreased 17.7% over the past 52 weeks, lagging behind Agilent’s performance during the same time period.
Story Continues
Despite Agilent Technologies’ weak price action, analysts are moderately optimistic about its prospects. A stock has a consensus rating of “Moderate Buy” from the 17 analysts in coverage, and the mean price target of $139.21 represents a premium of 10.2% to current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com